- ￥871 - 4690
- MedChemExpress(MCE)
- 美国
- HY-112181
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C, protect from light
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1695533-89-1
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1438.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥871.0 |
| 规格： | 5 mg | 产品价格： | ￥1839.0 |
| 规格： | 10 mg | 产品价格： | ￥2758.0 |
| 规格： | 25 mg | 产品价格： | ￥4690.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
KO-947
CAS No. : 1695533-89-1
MCE 国际站：KO-947
产品活性：KO-947是有效和选择性的 ERK1/2 激酶抑制剂，在MAPK途径失调的肿瘤中具有潜在效用。
研究领域：MAPK/ERK Pathway | Stem Cell/Wnt
作用靶点：ERK
In Vitro: KO-947 is a 10 nM inhibitor of ERK with at least 50-fold selectivity against a panel of 450 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations.
In Vivo: In cell-line derived xenograft studies, KO-947 profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly. Intermittent dosing enables comparable antitumor activity at reduced dose-intensity.
相关产品：Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Highly Selective Inhibitors Library | Serine/Threonine Kinase Inhibitor Library | PD98059 | Yoda 1 | SCH772984 | TBHQ | Tauroursodeoxycholate | Ulixertinib | Honokiol | Astragaloside IV | Piperlongumine | Ravoxertinib | Temuterkib | C16-PAF | Lidocaine | FR 180204 | BIX02189 | XMD8-92 | MK-8353 | 6-OAU | Patritumab | trans-Zeatin | SEW2871 | Urolithin B | VX-11e | ASN007 | Pamoic acid | Pachymic acid | AG126 | Lysophosphatidylcholines
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验网络 幽门螺杆菌感染947例临床分析 我院自1994-11～1996-04共对1448名患者进行纤维胃镜检查并做幽门螺杆菌（Hp）检查，其中Hp阳性947例。现报告如下。 1 对象和方法 1.1 对象 本组Hp阳性947例，男566例，女381例，男女之比1.49.1。年龄11岁～81岁。20岁95例（10.0％）；男39例，女
身高组段（1） 频数（2） 累计频数*（3） 累计频率（%）（4） 概率单位（5） 162～ 1 1 0.9 2.63 164～ 4 5 4.5 3.30 166～ 9 14 12.7 3.86 168～ 13 27 24.5 4.31 170～ 19 46 41.8 4.79 172～ 27 73 66.4 5.42 174～ 16 89 80.9 5.87 176～ 8 97 88.2 6.19 178～ 8 105 95.5 6.70 180～ 3 108 98.2
Design and Generation of Gene‐Targeting Vectors
are followed by protocols for the construction of vectors to generate knockout (KO), conditional KO, and subtle mutant alleles. Curr. Protoc. Mouse Biol. 1:199?211. © 2011 by John Wiley & Sons, Inc. Keywords: gene targeting; conditional KO
技术资料暂无技术资料 索取技术资料
